8-KOther EventsExhibits & Filings

PFIZER INC 8-K Report, Corporate Update (Oct 12, 2010)

Filed October 12, 2010For Securities:PFE

Summary

Pfizer Inc. (PFE) filed an 8-K on October 12, 2010, to announce a significant development: the execution of an Agreement and Plan of Merger with King Pharmaceuticals, Inc. The filing indicates that a wholly-owned subsidiary, Parker Tennessee Corp., is involved in this transaction. This merger agreement represents a material event for Pfizer, signaling a strategic move to expand or consolidate its operations through the acquisition of King Pharmaceuticals. Investors should view this announcement as a key indicator of Pfizer's growth and M&A strategy. The details of the merger, including the purchase price and strategic rationale, would typically be found in the referenced press release (Exhibit 99.1). This filing triggers increased investor scrutiny regarding the financial implications and potential synergies arising from this acquisition.

Key Highlights

  • 1Pfizer Inc. announced the execution of an Agreement and Plan of Merger with King Pharmaceuticals, Inc. on October 11, 2010.
  • 2A wholly-owned subsidiary, Parker Tennessee Corp., is a party to the merger agreement.
  • 3The filing's primary purpose is to report on this significant merger event.
  • 4This 8-K filing indicates a major strategic initiative by Pfizer, likely involving the acquisition of King Pharmaceuticals.
  • 5The press release detailing the merger agreement is attached as Exhibit 99.1 and incorporated by reference.

Frequently Asked Questions

The main purpose of this 8-K filing is to report that Pfizer Inc. has entered into an Agreement and Plan of Merger with King Pharmaceuticals, Inc.

Pfizer Inc., through its subsidiary Parker Tennessee Corp., is entering into a merger agreement with King Pharmaceuticals, Inc. This indicates Pfizer is acquiring King Pharmaceuticals.

More details about the merger agreement can be found in the press release dated October 12, 2010, which is attached as Exhibit 99.1 to this 8-K filing and incorporated by reference.

This merger signifies a strategic move by Pfizer, likely aimed at expanding its product portfolio, market presence, or therapeutic areas through the acquisition of King Pharmaceuticals.